Surgical Hemostat, Internal Tissue Sealant, and Adhesion Barrier Market

Surgical Hemostat, Internal Tissue Sealant, and Adhesion Barrier Market Outlook (2024 to 2034)

Expanding at a CAGR of 8.9%, the global surgical hemostat, internal tissue sealant, and adhesion barrier market is projected to increase from a valuation of US$ 5.72 billion in 2024 to US$ 13.46 billion by the end of 2034. Surgical hemostats, internal tissue sealants, and adhesion barriers are implants that prevent internal scarring caused by tissue or organ adhesion. Medical devices and applications such as hemostats, internal compression, and hemostatic barriers are being used to manage excessive bleeding following surgery or during dental procedures.

Hemostats are medical devices used in dental procedures to stop excessive blood loss in patients who are bleeding heavily. They are also referred to as hemostatic forceps, arterial pressure gauges, or devices that resemble pean screws. Adhesive barriers are also used during gynecological, abdominal, cardiovascular, orthopedic/medicinal, and urological surgeries that involve internal tissues and organs.

Global market for surgical hemostats, internal tissue sealants, and adhesion barriers is expanding due to multiple factors such as robust healthcare systems and well-established reimbursement policies for healthcare procedures.

Key Market Growth Drivers

• Growing demand for cardiovascular, orthopedic, digestive, and other surgical procedures, along with the growing geriatric population across the globe, is set to contribute to the expansion of the surgical hemostat, internal tissue sealant, and adhesion barrier market size.
• The market for internal tissue sealants, adhesion barriers, and surgical hemostats is growing due to several factors, including an increase in sports injuries and spinal problems, an increase in the number of surgeries performed, and an increased need for compelling blood loss administration.
• Manufacturers are showing increasing interest in this industry to capture a significant portion of the global market, leading to heightened competition and market expansion.
• Increasing number of surgeries worldwide is one of the major drivers for the surgical hemostat, internal tissue sealant, and adhesion barrier market growth.

Report Attributes	Details
Surgical Hemostat, Internal Tissue Sealant, and Adhesion Barrier Market Size (2024E)	US$ 5.72 Billion
Forecasted Market Value (2034F)	US$ 13.46 Billion
Global Market Growth Rate (2024 to 2034)	8.9% CAGR
East Asia Market Growth Rate (2024E)	9.9% CAGR
North America Market Share (2024E)	53.8%
Sales of Internal Tissue Sealants (2024E)	US$ 2.24 Billion
Key Companies Profiled	Ethicon (Johnson & Johnson) Baxter International Inc. Integra LifeSciences Holdings Corporation Pfizer Inc. Tissuemed Ltd. Sanofi Braun Melsungen AG C.R. Bard Inc. CryoLife Inc. Cohera Medical Inc. CSL Behring

Why are Sales of Surgical Hemostats, Internal Tissue Sealants, and Adhesion Barriers Rising Rapidly?

“Rising Incidence of Cardiovascular Diseases across Regions”

Increasing incidence of cardiovascular diseases is primarily responsible for the growing demand for tissue sealants and hemostats. The launch of more products aimed at controlling bleeding during surgeries is fueling global sales of surgical hemostats, internal tissue sealants, and adhesion barriers.

Depending on the type of injury, various hemostatic methods are employed, often composed of substances such as cellulose, gelatin, and oxidized regenerated collagen. Hemostats are available in different forms, including sponge, sheet, pad, matrix, gel, and powder, and find application in various surgical procedures, from general to neurological, thus driving market growth for these products.

What are the Hindrances to Market Growth?

“High Cost of Surgical Hemostats and Internal Tissue Sealants”

Treatment for internal tissue sealants, adhesion barriers, and surgical hemostats is becoming increasingly expensive. The high costs of these components are restricting their worldwide sales. Research and development into surgical hemostats and tissue sealants also entail increased expenses for manufacturers. The rising cost of research & development means increased cost of the raw materials used for the preparation of polymers. The prolonged R&D process is also impeding market growth.

Country-wise Insights

North America is estimated to hold 50% surgical hemostat, internal tissue sealant, and adhesion barrier market share. Over the course of the forecast period from 2024 to 2034, North America is projected to maintain its leading position in the worldwide market. This is because cases of small bowel obstruction (SBO) are increasing in the region. Adhesion barriers are required to stop scar or adhesion formation in SBO.

Which Trends are Advantageous to Manufacturers in the United States?

“Increasing Number of Heart Transplants”

Attribute	United States
Market Value (2024E)	US$ 2.4 Billion
Growth Rate (2024 to 2034)	9.6% CAGR
Projected Value (2034F)	US$ 6 Billion

The United States is estimated to account for 75% share of the North American market in 2024 due to increasing cases of cardiovascular diseases among more people in the country.

• As per the American Heart Association's Heart Disease and Stroke Statistics report released on February 22, 2022, 3,658 heart transplants were carried out in the country in 2020. California (496) had the maximum number of cases of heart transplants, followed by Texas (302), Florida (288), and New York (250). The most commonly performed procedure was cardiac catheterization.
• Inpatient procedures performed in the United States for patients included an estimated 480,000 percutaneous transluminal coronary angioplasties, 371,000 inpatient bypass procedures, 1,016,000 inpatient diagnostic cardiac catheterizations, 86,000 carotid endarterectomies, and 351,000 pacemaker procedures.

Why are Surgical Hemostat and Internal Tissue Sealant Producers Turning to Japan?

“Shift toward Minimally Invasive Surgical Techniques Fueling Demand for Hemostatic Products”

Attribute	Japan
Market Value (2024E)	US$ 200.7 Million
Growth Rate (2024 to 2034)	10% CAGR
Projected Value (2034F)	US$ 472.2 Million

Japan holds a significant share of the market in East Asia, and product sales are projected to rise at a noteworthy pace through 2034 due to technological advancements, rising surgical procedures, and the increasing prevalence of cardiovascular disorders among the aging population in the country. There is a shift toward minimally invasive surgical techniques that necessitates the development of hemostatic products tailored to these procedures, thus driving market growth. This is one of the major surgical hemostat, internal tissue sealant, and adhesion barrier market trends.

• TENALEAF is a sheet-type absorbable adhesion barrier that is made in Japan. In February 2023, it was approved as a medical device by Gunze Limited, a Japan-based company. With its moderate adhesive strength allowing for conformable placement and easy manipulation, this product is offering surgeons a new option during open and minimally invasive surgeries.

Category-wise Insights

By product, the market is segmented into hemostats, internal tissue sealants, and adhesion barriers. Internal tissue sealants dominate the market attributed to increased wound-sealing needs and growing demand for affordable medical products in developing nations. Manufacturers are investing in R&D to enhance the functions of these devices. Hospitals hold a significant market share due to increased surgical procedures.

What are the Main Contributors to Rising Adoption of Internal Tissue Sealants?

“Growing Emphasis on Development of Bioresorbable Sealants”

Attribute	Internal Tissue Sealants
Segment Value (2024E)	US$ 2.24 Billion
Growth Rate (2024 to 2034)	9.1% CAGR
Projected Value (2034F)	US$ 5.35 Billion

Manufacturers are dedicating resources to research and development to produce sealants with enhanced features, including improved sealing ability, reduced toxicity, and faster healing times. The development of bioresorbable sealants, eliminating the need for removal post-healing, is also gaining momentum.

Why Do Hospitals Extensively Use Hemostats, Tissue Sealants, and Adhesion Barriers?

“Access to Advanced Medical Technologies and Resources to Ensure Efficient Equipment Use”

Attribute	Hospitals
Segment Value (2024E)	US$ 3.93 Billion
Growth Rate (2024 to 2034)	8.8% CAGR
Projected Value (2034F)	US$ 9.15 Billion

Based on end user, the surgical hemostat, internal tissue sealant, and adhesion barrier market is categorized into hospitals, ambulatory surgical centers, and specialty clinics. Hospitals account for 70% market share in 2024. Hospitals carry out a wide range of surgical procedures for diverse medical conditions, which necessitates the use of hemostats, sealants, and adhesion barriers. Hospitals have advanced medical technologies and resources to ensure efficient application and monitoring of these products during surgeries.

Competitive Landscape

Key players in the surgical hemostat, internal tissue sealant, and adhesion barrier market are Ethicon (Johnson & Johnson), Baxter International Inc., Integra LifeSciences Holdings Corporation, Pfizer Inc., Tissuemed Ltd., Sanofi, Braun Melsungen AG, C.R. Bard Inc., CryoLife Inc., Cohera Medical Inc., and CSL Behring.

• Salarius Pharmaceuticals, Inc., a biopharmaceutical company based in the United States, released preclinical data on December 5, 2022. SP-3164 is an experimental small molecule protein degrader or molecular glue that has the potential to exhibit enhanced anti-multiple myeloma activity. It inhibited the growth of cancer in a mouse model and caused lab-grown cancer cells to die. Therefore, it might be able to treat hematological cancers.
• DendroPrime is a thiol-ene-based coating that was assessed to determine its effectiveness as an adhesion barrier between a plate and flexor tendon in in-vivo models, according to an article published in the Journal of Hand Surgery on June 19, 2020. When DendroPrime was applied to the implanted plates, the mobility in the distal interphalangeal joint (DIP) joint was statistically significantly better than when the bare metal plates were left uncoated. In addition, the coating stopped soft tissue from growing around the implant, making removal simpler than it would have been for uncoated plates.
• The United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) approved RevBio Inc., a biotechnology company based in the United States, to launch a clinical trial for an enhanced version of its dental bone adhesive biomaterial Tetranite on September 15, 2022. Fifteen patients were to participate in clinical trials to evaluate the effectiveness and safety of dental implants that are stabilized right away after tooth extractions.

Segmentation of Surgical Hemostat, Internal Tissue Sealant, and Adhesion Barrier Market Research

• By Product Type :

  • Hemostats
  • Internal Tissue Sealants
  • Adhesion Barriers

• By Application :

  • Surgical Applicants
  • Trauma Cases

• By End User :

  • Hospitals
  • Ambulatory Surgical Centers
  • Specialty Clinics

• By Region :

  • North America
  • Europe
  • Latin America
  • East Asia
  • South Asia & Oceania
  • Middle East & Africa